JP5894174B2 - グルカゴンを含む新規組成物 - Google Patents

グルカゴンを含む新規組成物 Download PDF

Info

Publication number
JP5894174B2
JP5894174B2 JP2013537210A JP2013537210A JP5894174B2 JP 5894174 B2 JP5894174 B2 JP 5894174B2 JP 2013537210 A JP2013537210 A JP 2013537210A JP 2013537210 A JP2013537210 A JP 2013537210A JP 5894174 B2 JP5894174 B2 JP 5894174B2
Authority
JP
Japan
Prior art keywords
glucagon
composition
concentration
composition according
benzethonium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501707A5 (https=
JP2014501707A (ja
Inventor
ジェゼック，ジャン
キングストン デラム，バリー
キングストン デラム，バリー
Original Assignee
アレコー リミテッド
アレコー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレコー リミテッド, アレコー リミテッド filed Critical アレコー リミテッド
Publication of JP2014501707A publication Critical patent/JP2014501707A/ja
Publication of JP2014501707A5 publication Critical patent/JP2014501707A5/ja
Application granted granted Critical
Publication of JP5894174B2 publication Critical patent/JP5894174B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2013537210A 2010-11-03 2011-11-03 グルカゴンを含む新規組成物 Expired - Fee Related JP5894174B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40978510P 2010-11-03 2010-11-03
US40972310P 2010-11-03 2010-11-03
US61/409,785 2010-11-03
US61/409,723 2010-11-03
US201161503104P 2011-06-30 2011-06-30
US201161503178P 2011-06-30 2011-06-30
US61/503,104 2011-06-30
US61/503,178 2011-06-30
PCT/GB2011/052139 WO2012059762A1 (en) 2010-11-03 2011-11-03 Novel composition comprising glucagon

Publications (3)

Publication Number Publication Date
JP2014501707A JP2014501707A (ja) 2014-01-23
JP2014501707A5 JP2014501707A5 (https=) 2014-12-04
JP5894174B2 true JP5894174B2 (ja) 2016-03-23

Family

ID=44913349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537210A Expired - Fee Related JP5894174B2 (ja) 2010-11-03 2011-11-03 グルカゴンを含む新規組成物

Country Status (6)

Country Link
US (1) US9023985B2 (https=)
EP (1) EP2635296B1 (https=)
JP (1) JP5894174B2 (https=)
CA (1) CA2816114C (https=)
ES (1) ES2533601T3 (https=)
WO (2) WO2012059764A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP7001584B2 (ja) * 2015-09-04 2022-01-19 ラティチュード ファーマシューティカルズ インコーポレイテッド 安定化されたグルカゴン溶液
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
BR112018075250A2 (pt) 2016-06-07 2019-03-12 Adocia composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
AU2018380993A1 (en) 2017-12-07 2020-06-11 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
KR20240171195A (ko) 2017-12-07 2024-12-06 아도시아 인간 글루카곤 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
US10987426B2 (en) 2017-12-07 2021-04-27 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
FR3083087A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US20190275110A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
FR3067247A1 (fr) 2018-06-07 2018-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
KR20210144606A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
JPH0651637B2 (ja) 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
AR019727A1 (es) * 1998-06-30 2002-03-13 Takeda Chemical Industries Ltd Composicion farmaceutica
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP4147234B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US7115791B2 (en) 2002-12-19 2006-10-03 Exxonmobil Chemical Patents Inc. Method and apparatus for controlling effluent composition in oxygenates to olefins conversion
KR20070029276A (ko) 2004-06-29 2007-03-13 디오벡스, 인코포레이티드 인슐린으로 인한 저혈당증을 예방하고 조절하기 위한조성물 및 방법
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20100061480A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 글루카곤（１－２９） 단독 또는 뉴로펩티드 ｗ３０과의 배합물의 용도
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
DK2490708T3 (da) 2009-10-22 2013-04-15 Biodel Inc Stabiliserede glucagon-opløsninger
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions

Also Published As

Publication number Publication date
EP2635296A1 (en) 2013-09-11
ES2533601T3 (es) 2015-04-13
EP2635296B1 (en) 2014-12-24
JP2014501707A (ja) 2014-01-23
WO2012059764A1 (en) 2012-05-10
CA2816114C (en) 2019-02-12
CA2816114A1 (en) 2012-05-10
WO2012059762A1 (en) 2012-05-10
US9023985B2 (en) 2015-05-05
US20130252893A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
JP5894174B2 (ja) グルカゴンを含む新規組成物
CN104994864B (zh) 包含人胰岛素或其类似物或衍生物的稳定水性组合物
KR102482664B1 (ko) 신규한 제제
US11278624B2 (en) Formulations
US10888616B2 (en) Stabilized glucagon solutions
US20200222508A1 (en) Glucagon-like peptide 1 (glp-1) receptor agonist compositions
CN112004521A (zh) 用于递送胰岛素化合物的医用输注泵系统
EP3773473A1 (en) Medical infusion pump system for the delivery of an insulin compound
AU2013265210B2 (en) Somatostatin receptor agonist formulations
CN107106659B (zh) 肠胃外胰高血糖素制剂
AU2013368990B2 (en) Pharmaceutical composition
WO2017221026A1 (en) Novel composition
CA3238895A1 (en) High-concentration administration formulation of hgh fusion protein
EP2861209A1 (en) Somatostatin receptor agonist formulations
BR112015011179B1 (pt) Composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160225

R150 Certificate of patent or registration of utility model

Ref document number: 5894174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees